Group 1 - The Hong Kong biotechnology stocks experienced a collective decline, with notable drops in several companies [1] - WuXi AppTec (02126) saw a decrease of 12.95%, closing at 4.840 [2] - BioNTech (06952) fell by 12.53%, with a latest price of 13.750 [2] Group 2 - Other companies such as Valiant (09887) and Beihai Kangcheng (01228) also reported significant declines of 9.93% and 9.75% respectively [2] - The decline extended to companies like Saint Noble (02257) and MIRXES (02629), which dropped by 9.64% and 8.43% [2] - Overall, the biotechnology sector is facing downward pressure, impacting multiple firms [1]

Group 1 - Hong Kong biopharmaceutical stocks weakened again in the afternoon on August 28, with WuXi AppTec and Bionet falling over 12% [1] - The decline in these stocks indicates a potential trend in the biopharmaceutical sector within the Hong Kong market [1] - The performance of these companies may reflect broader market sentiments and investor confidence in the biopharmaceutical industry [1]

Market Overview - The Hong Kong stock market experienced a collective decline in the morning session, with the Hang Seng Index falling by 0.66%, narrowly holding above 25,000 points, while the Hang Seng China Enterprises Index dropped by 0.86% and the Hang Seng Tech Index decreased by 1.04%, marking three consecutive days of decline [2][2][2] - Southbound capital recorded a net sell-off exceeding 10 billion HKD [2] Sector Performance - Major technology stocks, which serve as market indicators, showed collective weakness, particularly Meituan, which plummeted over 10% post-earnings, marking the worst performance. Alibaba and JD.com fell nearly 4%, while Baidu dropped over 1%. Xiaomi and Tencent also experienced declines [2][2][2] - The biopharmaceutical sector continued to decline due to impending drug tariffs, with innovative drug companies facing significant drops, including a more than 12% decline for BGI Genomics, alongside declines for Kangfang Bio, Zai Lab, WuXi Biologics, and BeiGene [2][2][2] - Chinese electric vehicle stocks in the US market also fell, leading to a collective drop in Hong Kong's new energy vehicle sector. Other sectors such as new consumption, steel, building materials, beer, heavy machinery, catering, and gambling stocks also saw declines [2][2][2] Positive Trends - Institutions are optimistic about the accelerated replacement of domestic chips, leading to a significant rise in semiconductor stocks, with SMIC surging over 8% and approaching historical highs [2][2][2] - Financial stocks, including domestic banks, Chinese brokerage firms, and domestic insurance stocks, generally performed actively, while oil and rare earth concept stocks saw widespread increases [2][2][2]

智通财经APP获悉，博安生物(06955)绩后跌超8%，截至发稿，跌7.06%，报14.61港元，成交额9830.77 万港元。 消息面上，博安生物发布中期业绩，上半年收入人民币3.93亿元，同比增加8.4%；毛利为人民币2.83亿 元，同比基本持平；母公司拥有人应占溢利为人民币2051.4万元，同比减少66.7%。期内收入增加主要 是由于产品(博优诺、博优倍及博洛加)销售较截至2024年6月30日止六个月持续增长15.9%至人民币3.853 亿元。 值得注意的是，8月9日，博安生物宣布，其自主研发的博优平(度拉糖肽注射液)已获得国家药品监督管 理局的上市批准，用于成人2型糖尿病患者的血糖控制。该产品是全球首个且当前唯一获批上市的度易 达(英文商品名：Trulicity)的生物类似药，国内尚无其他国产度拉糖肽注射液进入上市许可申请阶段。 博优平在中国大陆的商业化由博安生物与上药控股有限公司(上药控股)合作开展。 ...

博安生物(06955)绩后跌超8%，截至发稿，跌7.06%，报14.61港元，成交额9830.77万港元。 消息面上，博安生物发布中期业绩，上半年收入人民币3.93亿元，同比增加8.4%；毛利为人民币2.83亿 元，同比基本持平；母公司拥有人应占溢利为人民币2051.4万元，同比减少66.7%。期内收入增加主要 是由于产品(博优诺、博优倍及博洛加)销售较截至2024年6月30日止六个月持续增长15.9%至人民币3.853 亿元。 值得注意的是，8月9日，博安生物宣布，其自主研发的博优平(度拉糖肽注射液)已获得国家药品监督管 理局的上市批准，用于成人2型糖尿病患者的血糖控制。该产品是全球首个且当前唯一获批上市的度易 达(英文商品名：Trulicity)的生物类似药，国内尚无其他国产度拉糖肽注射液进入上市许可申请阶段。 博优平在中国大陆的商业化由博安生物与上药控股有限公司(上药控股)合作开展。 ...

Core Viewpoint - The company reported a revenue of RMB 393.4 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase, while the net profit attributable to the parent company decreased by 66.7% to RMB 20.5 million [1][2]. Financial Performance - Revenue for the period was RMB 393.4 million, up from RMB 362.9 million in the same period last year [2]. - Gross profit remained relatively stable at RMB 282.6 million, compared to RMB 282.6 million in the previous year [2]. - The sales cost increased significantly to RMB 110.8 million from RMB 80.3 million, indicating a rise in operational expenses [2]. - Other income and gains decreased sharply to RMB 2.6 million from RMB 36.1 million [2]. - Research and development costs were reduced to RMB 58.6 million from RMB 85.8 million, reflecting a strategic focus on cost management [2]. - Administrative expenses slightly decreased to RMB 23.2 million from RMB 24.3 million [2]. - Selling and distribution expenses increased to RMB 159.8 million from RMB 134.2 million, indicating higher marketing efforts [2]. - Financial costs rose to RMB 19.5 million from RMB 12.6 million, impacting overall profitability [2]. Profitability Metrics - The profit before tax was RMB 20.5 million, down from RMB 61.7 million in the previous year [2]. - Basic earnings per share decreased to RMB 0.04 from RMB 0.12, reflecting the decline in net profit [2]. - Total comprehensive income for the period was RMB 20.4 million, significantly lower than RMB 61.6 million from the previous year [2].

格隆汇8月27日丨博安生物(06955.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币3.93亿 元，同比增加8.4%；毛利为人民币2.83亿元，同比基本持平；母公司拥有人应占溢利为人民币2051.4万 元，同比减少66.7%；基本每股盈利人民币0.04元。期内收入增加主要是由于产品(博优诺®、博优倍® 及博洛加®)销售较截至2024年6月30日止六个月持续增长15.9%至人民币3.853亿元。 ...

Core Viewpoint - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, reflecting an 8.39% year-on-year increase, while the net profit attributable to shareholders decreased by 66.74% to 20.514 million RMB [1] Revenue Performance - The revenue increase was primarily driven by the sales growth of products (Bo Younuo, Bo Youbei, and Bo Luojia), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]

公告称，收入增加主要是由于产品(博优诺®、博优倍®及博洛加®)销售较截至2024年6月30日止六个月 持续增长15.9%至3.85亿元。 智通财经APP讯，博安生物(06955)发布截至2025年6月30日止六个月的中期业绩，收入3.93亿元(人民 币，下同)，同比增加8.39%;股东应占溢利2051.4万元，同比减少66.74%;每股基本盈利0.04元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 截 至2025年6月30日止六個月的中期業績公告 財務摘要 1. 收 入 截 至2025年6月30日 止 六 個 月，本 集 團 的 收 入 約 為 人 民 幣393.4百 萬 元， 較截至2024年6月30日止六個月的人民幣362.9百萬元增加約人民幣30.5 百 萬 元，同 比 增 長8.4%。該 增 加 主 要 是 由 於 產 品（博 優 諾®、博 優 倍®及 博 洛 加®）銷售較截至2024年6月30日止六個月持續增長15.9%至人民幣385.3 百 萬 元。 2. ...